Statistically different p-Tau/t-Tau ratios in AD patients were found with respect to the control population in Arrozi’s study, but further research in larger cohorts of patients is needed to confirm the validity of this biofluid for tauopathies monitoring [48]. The gene discussed is MAPT; the disease is Alzheimer disease.